Home / News / Research

Research

Telling the Quacks from the Cures

MDF is also happy to help you understand whether something is in a legitimate clinical trial, an approved therapy…or not.

New and Important Review Articles on DM

Important review articles on disease mechanisms of and therapy development for DM have recently been published.

Patient-Reported Data to Guide Care and a Cure for DM

The UK DM Patient Registry reports on disease burden for 556 patients with a confirmed diagnosis of DM1.

NIH Update—NINDS Program Project Grants (P01)

MDF shares an update on program project grants from the NINDS.

Reduced MBNL1 Precedes Structural and Functional Changes in the DM1 Mouse Brain

A new DM1 mouse model, with postnatal expression of expanded CUG repeat RNA in the brain, implicates reduced MBNL1 and MBNL2 in the staging of pathological and functional changes.

Join Us at the 2017 MDF Annual Conference

Registration is open! Register now for the 2017 MDF Annual Conference

MDF Launches First MDF DM Day in Iowa

MDF is pleased to announce the launch of a new program, MDF DM Days. These special one-day free events will be held in three locations across the U.S. in 2017, bringing together clinicians, researchers and MDF community members to share information and resources.

Epigenetics Underlying the Parent of Origin Effect in CDM

Epigenetic modifications upstream of an expanded DMPK allele may underlie the maternal bias in the inheritance of CDM.

A Biomarker for Cardiac Dysfunction in DM1?

A multi-center study suggests serum cardiac troponin-1 levels predict risks of left ventricular dysfunction in DM1 patients.

Using Gene Editing to Correct DM

A potentially revolutionary technology may allow development of a drug for DM that can correct a patient’s DNA by selectively removing the expanded CTG and CCTG repeats in DM1 and DM2, respectively.

Partners

© Myotonic Dystrophy Foundation. All rights reserved.